Ngā hua rapu kaituhi :: APM

1

Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted cancer immunotherapy strategies mā Ryan J. Hartmaier, Jehad Charo, David Fabrizio, Michael E. Goldberg, Lee A. Albacker, William Pao, Juliann Chmielecki

I whakaputaina 2017

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
2

Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence mā Samuel J. Klempner, David Fabrizio, Shalmali Bane, Marcia Reinhart, Tim Peoples, Siraj M. Ali, Ethan S. Sokol, Garrett M. Frampton, Alexa B. Schrock, Rachel Anhorn, Prasanth Reddy

I whakaputaina 2019

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
3

DRAGON: A Member of the Repulsive Guidance Molecule-Related Family of Neuronal- and Muscle-Expressed Membrane Proteins Is Regulated by DRG11 and Has Neuronal Adhesive Properties mā Tarek A. Samad, Ashok Srinivasan, Laurie A. Karchewski, Sung‐Jin Jeong, Jason Campagna, Ru‐Rong Ji, David Fabrizio, Ying Zhang, Herbert Y. Lin, Esther Bell, Clifford J. Woolf

I whakaputaina 2004

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
4

Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma mā Celina Ang, Samuel J. Klempner, Siraj M. Ali, Russell W. Madison, Jeffrey S. Ross, Eric A. Severson, David Fabrizio, Aaron M. Goodman, Razelle Kurzrock, James Suh, Sherri Z. Millis

I whakaputaina 2019

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
5

Prevalence of<i>PDL1</i>Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors mā Aaron M. Goodman, David Piccioni, Shumei Kato, Amélie Boichard, Huan‐You Wang, Garrett M. Frampton, Scott M. Lippman, Caitlin Connelly, David Fabrizio, Vincent A. Miller, Jason K. Sicklick, Razelle Kurzrock

I whakaputaina 2018

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
6

Prevalence of High Tumor Mutational Burden and Association With Survival in Patients With Less Common Solid Tumors mā Changxia Shao, Gerald Li, Lingkang Huang, Scott K. Pruitt, Emily Castellanos, Garrett M. Frampton, Kenneth R. Carson, Tamara Snow, Gaurav Singal, David Fabrizio, Brian M. Alexander, Fan Jin, Wei Zhou

I whakaputaina 2020

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
7

Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population mā C. Benedikt Westphalen, Matthew Krebs, C. Le Tourneau, Ethan Sokol, Sophia L. Maund, Timothy R. Wilson, Dexter X. Jin, Justin Y. Newberg, David Fabrizio, L. Véronèse, M. Thomas, Filippo de Braud

I whakaputaina 2021

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
8

High Tumor Mutational Burden Correlates with Longer Survival in Immunotherapy-Naïve Patients with Diverse Cancers mā Paul Riviere, Aaron M. Goodman, Ryosuke Okamura, Donald A. Barkauskas, Theresa J. Whitchurch, Suzanna Lee, Noor Khalid, Rachel Collier, Manvita Mareboina, Garrett M. Frampton, David Fabrizio, Andrew B. Sharabi, Shumei Kato, Razelle Kurzrock

I whakaputaina 2020

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
9

DRAGON, a Bone Morphogenetic Protein Co-receptor mā Tarek A. Samad, Anuradha Rebbapragada, Esther Bell, Ying E. Zhang, Yisrael Sidis, Sung‐Jin Jeong, Jason Campagna, Stephen Perusini, David Fabrizio, Alan L. Schneyer, Herbert Y. Lin, Ali H. Brivanlou, Liliana Attisano, Clifford J. Woolf

I whakaputaina 2005

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
10

Blood-based biomarkers for cancer immunotherapy: Tumor mutational burden in blood (bTMB) is associated with improved atezolizumab (atezo) efficacy in 2L+ NSCLC (POPLAR and OAK) mā David R. Gandara, Marcin Kowanetz, Tony Mok, Achim Rittmeyer, Louis Fehrenbacher, David Fabrizio, Geoff Otto, Christine M. Malboeuf, Daniel S. Lieber, Sarah Paul, Lukas C. Amler, Todd Riehl, Erica Schleifman, Craig Cummings, P. Hegde, Wei Zou, Anna Sandler, M. Ballinger, David S. Shames

I whakaputaina 2017

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
11

Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in <i>ERBB2</i> and <i>ERBB3</i> mā Jeffrey S. Ross, Marwan Fakih, Siraj M. Ali, Julia A. Elvin, Alexa B. Schrock, James Suh, Jo‐Anne Vergilio, Shakti Ramkissoon, Eric A. Severson, Sugganth Daniel, David Fabrizio, Garrett M. Frampton, James Sun, Vincent A. Miller, Philip J. Stephens, Laurie M. Gay

I whakaputaina 2018

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
12

Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition mā David Fabrizio, Thomas J. George, Richard F. Dunne, Garrett M. Frampton, James Sun, Kyle Gowen, Mark Kennedy, Joel Greenbowe, Alexa B. Schrock, Aram F. Hezel, Jeffrey S. Ross, P. J. Stephens, Siraj M. Ali, Vincent A. Miller, Marwan Fakih, Samuel J. Klempner

I whakaputaina 2018

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
13

A Novel Next-Generation Sequencing Approach to Detecting Microsatellite Instability and Pan-Tumor Characterization of 1000 Microsatellite Instability–High Cases in 67,000 Patient S... mā Sally E. Trabucco, Kyle Gowen, Sophia L. Maund, Eric M. Sanford, David Fabrizio, Michael J. Hall, Evgeny Yakirevich, Jeffrey P. Gregg, Phil Stephens, Garrett M. Frampton, Priti S. Hegde, Vincent A. Miller, Jeffrey S. Ross, Ryan J. Hartmaier, Shih-Min A. Huang, James Sun

I whakaputaina 2019

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
14

Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial mā Edward S. Kim, Vamsidhar Velcheti, Tarek Mekhail, Cindy Yun, Sarah M. Shagan, Sylvia Hu, Young Kwang Chae, Ticiana Leal, Jonathan E. Dowell, Michaela L. Tsai, Christopher Dakhil, Philip J. Stella, Yanling Jin, David S. Shames, Erica Schleifman, David Fabrizio, See Phan, Mark A. Socinski

I whakaputaina 2022

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
15

Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors mā Jessica Lee, Smruthy Sivakumar, Alexa B. Schrock, Russell W. Madison, David Fabrizio, Ole Gjoerup, Jeffrey S. Ross, Garrett M. Frampton, Pavel Napalkov, Meagan Montesion, Jennifer L. Schutzman, Xin Ye, Priti S. Hegde, Misako Nagasaka, Geoffrey R. Oxnard, Ethan Sokol, Sai‐Hong Ignatius Ou, Zhen Shi

I whakaputaina 2022

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
16

A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer mā Zoe J. Assaf, Wei Zou, Alexander D. Fine, Mark A. Socinski, Amanda Young, Doron Lipson, Jonathan F. Freidin, Mark Kennedy, Eliana Polisecki, Makoto Nishio, David Fabrizio, Geoffrey R. Oxnard, Craig Cummings, Anja Rode, Martin Reck, Namrata S. Patil, Mark Lee, David S. Shames, Katja Schulze

I whakaputaina 2023

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
17

Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer mā Christopher J. Sweeney, Russell Petry, Chang Xu, Merrida Childress, Jie He, David Fabrizio, Ole Gjoerup, Samantha Morley, Timothy Catlett, Zoe J. Assaf, Kobe Yuen, Matthew Wongchenko, Kalpit Shah, Pratyush Gupta, Priti Hegde, Lincoln W. Pasquina, Sanjeev Mariathasan, Ryon P. Graf, Thomas Powles

I whakaputaina 2024

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
18

Comprehensive genomic profiles of metastatic and relapsed salivary gland carcinomas are associated with tumor type and reveal new routes to targeted therapies mā Jeffrey S. Ross, Laurie M. Gay, K. Wang, Jo‐Anne Vergilio, James Suh, Shakti Ramkissoon, Hilary Somerset, Jennifer M. Johnson, Jeffery S. Russell, Siraj M. Ali, Alexa B. Schrock, David Fabrizio, Garrett M. Frampton, V.A. Miller, Philip J. Stephens, Julia A. Elvin, Daniel W. Bowles

I whakaputaina 2017

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
19

Final efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L no... mā Mark A. Socinski, Vamsidhar Velcheti, Tarek Mekhail, Y.K. Chae, Ticiana Leal, J.E. Dowell, Ming-Hung Tsai, Christopher Dakhil, Philip J. Stella, Vincent K. Shen, Sylvia Hu, S.M. Paul, David S. Shames, Erica Schleifman, David Fabrizio, Michaeł Nowicki, C. Yun, S. Phan, E.S. Kim

I whakaputaina 2019

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
20

A Novel HRD Signature Is Predictive of FOLFIRINOX Benefit in Metastatic Pancreatic Cancer mā Kuei‐Ting Chen, Russell W. Madison, Jay A. Moore, Dexter X. Jin, Zoë Fleischmann, Justin Y. Newberg, Alexa B. Schrock, Neeru Bhardwaj, Katherine T Lofgren, Jie He, Garrett M. Frampton, Priti Hegde, David Fabrizio, Michael J. Pishvaian, Ericka M. Ebot, Aatur D. Singhi, Ethan Sokol

I whakaputaina 2023

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i: